Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Alexion Pharma's Bloated Blockbuster Deal Still Haunts

Alexion Pharma's Bloated Blockbuster Deal Still Haunts

Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.

Merck Alzheimer's Drug Study Halted Early for Futility

Merck Alzheimer's Drug Study Halted Early for Futility

Independent study monitors concluded that there was "virtually no chance of finding a positive clinical effect."

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

VenBio accuses Immunomedics management of undervaluing and essentially giving away the cancer drug IMMU-132 because they were afraid of losing their jobs in a proxy vote.